A DESCRIPTIVE, RETROSPECTIVE ANALYSIS OF COVID-19 ANTIBODY THERAPY AND ITS EFFECTS ON MORBIDITY AND MORTALITY IN PATIENTS RECEIVING B-LYMPHOCYTE DEPLETING THERAPIES

INTRO: Patients receiving B-cell depleting or inhibiting therapies (BCDT), such as anti-CD20 monoclonal antibodies (CD20-MAB), are at risk for severe COVID-19. BCDT decreases production of neutralizing antibodies, causing delayed viral clearance and prolonged viral shedding. Passive antibody therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Simeunovic, G., Sullivan, L., Gentile, S., Brooks, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186901/
http://dx.doi.org/10.1016/j.ijid.2023.04.286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186901/
http://dx.doi.org/10.1016/j.ijid.2023.04.286

Ejemplares similares